ArticleCancer reports (Hoboken, N.J.)2025
Pediatric Radiation Oncology in the Era of COVID-19: A Single Institution Analysis.
Article in Cancer reports (Hoboken, N.J.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Disparities in Rural-Urban Cancer Care Outcomes among Pediatric, Adolescent, and Young Adult Populations: A Comprehensive Narrative Review.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2026Review
- Pediatric Radiation Oncology in the Era of COVID-19: A Single Institution Analysis.Cancer reports (Hoboken, N.J.) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsAs a result of the COVID-19 pandemic, health inequities have garnered heightened attention in the public consciousness. In particular, rural access to diagnosis and radiotherapy (RT) for pediatric oncology patients was markedly affected during this period. The fractionated nature of RT creates a transportation burden for this population. We reviewed our institutional experience with pediatric oncologic therapy at a tertiary academic center serving a primarily rural population over a large geographic area.
methodsPediatric patients aged ≤ 18 years diagnosed with cancer between 2018 and 2022 at our institution were investigated, and we identified the subset of patients who received RT at our institution. Patients were categorized as pre-COVID onset (diagnosed between 2018 and January 31, 2020) or post-COVID onset (diagnosed on or after January 31, 2020, to December 1st, 2022). Chi-Square and Student's t-tests were used to elucidate associations between patient demographics and treatment modalities in the pre- and post-COVID onset groups.
resultsA total of 114 patients were identified. For patients that received RT (n = 22), 4.5 times more patients traveled from rural counties post-COVID onset (p = 0.027). These patients also saw increased rates of central nervous system (CNS) and non-hematologic cancer diagnosis (p = 0.013 and 0.049, respectively). No difference was seen concerning race, patient age, or average distance traveled (p = 0.371, 0.249, and 0.420, respectively). No difference was seen in the estimated transportation cost incurred as a result of RT treatment (p = 0.144) or in treatment with concurrent chemotherapy (p = 0.245). For the entire cohort, no associations were seen concerning age, race, rural versus urban home county, cancer primary site, or in the prevalence of hematologic- or CNS-based cancers.
conclusionOur results highlight the importance of understanding barriers to care to improve outcomes in rural pediatric patients, as the burden of RT may be greater for these patients than for those living in urban counties. Further investigation into barriers to treatment among rural pediatric patients undergoing RT is warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.